Search

Displaying results 2441 - 2450 of 8412 in total
  1. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.

    Synonyms: p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine
  2. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  3. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    Eladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal and rare genetic disorder that ...

  4. Drug

    PF-5212372

    go.drugbank.com/drugs/DB19212
    Investigational

    PF-5212372 is under investigation in clinical trial NCT02795832 (A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis).

  5. Drug

    Adriforant

    go.drugbank.com/drugs/DB15027
    Investigational

    Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).

    Synonyms: PF-03893787
  6. Drug

    Zalifrelimab

    go.drugbank.com/drugs/DB15632
    Investigational

    Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).

  7. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    , the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or hepatic decompensation) due

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. … [L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells.

  9. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. … Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles;[L1452] thus, those who are allergic to [Asparaginase Escherichia coli] do

  10. Drug

    rCFP-10

    go.drugbank.com/drugs/DB21907
    Approved

    rCFP-10 is a recombinant culture filtrate protein of _Mycobacterium tuberculosis_ used as an ingredient in the diagnostic agent SIILTIBCY along with [rdESAT-6].[L53638]